Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
News Jan 23, 2008
Under a license agreement with Oxford BioMedica, MolMed’s TK therapy product employs Oxford BioMedica’s retroviral ex vivo gene delivery technology. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica.
China is poised to introduce a new regulation on gene editing in humans. A draft of the country’s new civil code lists human genes and embryos in a section on personality rights to be protected. Experiments on genes in adults or embryos that endanger human health or violate ethical norms can accordingly be seen as a violation of a person’s fundamental rights.READ MORE